Abilify Maintena (Aripiprazole LAI Monthly)

Abilify Maintena (Aripiprazole LAI Monthly) is filed as Long-Acting Injectable Antipsychotic. The sections below restate public label fields stored for this profile.

Class
Long-Acting Injectable Antipsychotic
Generic name
Aripiprazole LAI Monthly
Dosage forms
3 DOSAGE FORMS AND STRENGTHS For extended-release injectable suspension : 300 mg and 400 mg of lyophilized powder for reconstitution in: single-dose, pre-filled, dual chamber syringe single-dose vial The reconstituted extended-release injectable suspension is a uniform, homogeneous suspension that is opaque and milky-white in color. For extended-release injectable suspension: 300 mg and 400 mg strength lyophilized powder for reconstitution in ( 3 ): single-dose, pre-filled, dual chamber syringe single-dose vial
Manufacturer
Otsuka America Pharmaceutical, Inc.
Boxed warning
Yes

Approved uses

1 INDICATIONS AND USAGE ABILIFY MAINTENA (aripiprazole) is indicated: for the treatment of schizophrenia in adults for maintenance monotherapy treatment of bipolar I disorder in adults ABILIFY MAINTENA is an atypical antipsychotic indicated: for treatment of schizophrenia in adults ( 1 ) for maintenance monotherapy treatment of bipolar I disorder in adults ( 1 )

How it works

12.1 Mechanism of Action The mechanism of action of aripiprazole in the treatment of schizophrenia and bipolar I disorder is unknown. The efficacy of aripiprazole could be mediated through a combination of partial agonist activity at dopamine D 2 and serotonin 5-HT 1A receptors and antagonist activity at 5-HT 2A receptors.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death ( 5.1 ) ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )

Warnings and precautions

BOXED WARNING: WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ]. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death ( 5.1 ) ABILIFY MAINTENA is not approved for the treatment of patients with dementia-related psychosis ( 5.1 )

Contraindications

4 CONTRAINDICATIONS ABILIFY MAINTENA is contraindicated in patients with a known hypersensitivity to aripiprazole. Hypersensitivity reactions ranging from pruritus/urticaria to anaphylaxis have been reported in patients receiving aripiprazole [see Adverse Reactions (6.1 and 6.2) ] . Known hypersensitivity to aripiprazole ( 4 )

Adverse reactions

The following adverse reactions are discussed in more detail in other sections of the labeling: Increased Mortality in Elderly Patients with Dementia - Related Psychosis Use [see Boxed Warning and Warnings and Precautions (5.1) ] Cerebrovascular Adverse Reactions, Including Stroke in Elderly Patients with Dementia-Related Psychosis [see Boxed Warning and Warnings and Precautions (5.2) ] Neuroleptic Malignant Syndrome [see Warnings and Precautions (5.3) ] Tardive Dyskinesia [see Warnings and Precautions (5.4) ] Metabolic Changes [see Warnings and Precautions (5.5) ] Pathological Gambling and Other Compulsive Behaviors [see Warnings and Precautions (5.6) ] Orthostatic Hypotension and Syncope [see Warnings and Precautions (5.7) ] Falls [see Warnings and Precautions (5.8) ] Leukopenia, Neutropenia, and Agranulocytosis [see Warnings and Precautions (5.9) ] Seizures [see Warnings and Precautions (5.10) ] Potential for Cognitive and Motor Impairment [see Warnings and Precautions (5.11) ] Body Temperature Regulation [see Warnings and Precautions (5.12) ] Dysphagia [see Warnings and Precautions (5.13) ]

Dosage and administration

2 DOSAGE AND ADMINISTRATION Only to be administered by intramuscular injection in the deltoid or gluteal muscle by a healthcare professional ( 2.1 ) For patients naïve to aripiprazole, establish tolerability with oral aripiprazole prior to initiating ABILIFY MAINTENA ( 2.1 ) Recommended dosage is 400 mg administered monthly as a single injection. Dose can be reduced to 300 mg in patients with adverse reactions ( 2.2 ) There are two ways to initiate treatment with ABILIFY MAINTENA 1-day initiation: Administer two separate intramuscular injections of ABILIFY MAINTENA 400 mg and a single oral dose of aripiprazole 20 mg ( 2.2 ) 14-day initiation: In conjunction with first ABILIFY MAINTENA 400 mg dose, take 14 consecutive days of concurrent oral aripiprazole (10 mg to 20 mg) or current oral antipsychotic ( 2.2 ) Dosage adjustments are required for missed doses ( 2.3 ) Known CYP2D6 poor metabolizers: Recommended starting and maintenance dose is 300 mg administered monthly as a single injection ( 2.4 ) See full prescribing information for ABILIFY MAINTENA dosage modifications due to drug interactions ( 2.4 ). ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe ( 2.6 ), and 2) Vials ( 2.7 ). 2.1 Important Administration Information For patients who have never taken aripiprazole, establish tolerability with oral aripiprazole prior to initiating treatment with ABILIFY MAINTENA. Due to the half-life of oral aripiprazole (i.e., 75 hours and 94 hours for aripiprazole and dehydro-aripiprazole, respectively), it may take up to 2 weeks to fully assess tolerability. ABILIFY MAINTENA must be administered by intramuscular injection by a healthcare professional. Do not administer by any other route. For detailed preparation and administration instructions, [see Dosage and Administration (2.6 , 2.7) ] . 2.2 Recommended Dosage for ABILIFY MAINTENA The recommended dose of ABILIFY MAINTENA is 400 mg monthly (no sooner than 26 days after the previous injection). There are two ways to initiate treatment with ABILIFY MAINTENA in patients receiving oral antipsychotics: 1-day initiation: Administer two intramuscular injections of ABILIFY MAINTENA 400 mg in two different injection sites (in either the deltoid or gluteal muscle), and one dose of oral aripiprazole 20 mg on the first day of treatment with ABILIFY MAINTENA. Do not administer both injections into the same muscle. 14-day initiation: When ABILIFY MAINTENA injection is initiated in patients receiving oral aripiprazole administer one intramuscular injection of ABILIFY MAINTENA 400 mg in either the deltoid or gluteal muscle and continue treatment with oral aripiprazole (10 mg to 20 mg) for 14 consecutive days to achieve therapeutic aripiprazole concentrations during initiation of therapy. For patients already stable on another oral antipsychotic (and known to tolerate aripiprazole), administer one intramuscular injection of ABILIFY MAINTENA 400 mg in either the deltoid or gluteal muscle and continue treatment with the oral antipsychotic for 14 consecutive days to maintain therapeutic antipsychotic concentrations during initiation of therapy. If there are adverse reactions with the 400 mg dosage, the dosage may be reduced to 300 mg once monthly. 2.3 Missed Doses If the second or third doses are missed: If more than 4 weeks and less than 5 weeks have elapsed since the last injection, administer the injection as soon as possible . If more than 5 weeks have elapsed since the last injection, restart treatment with either 1-day initiation or 14-day initiation with ABILIFY MAINTENA [see Dosage and Administration (2.2) ] . If the fourth or subsequent doses are missed: If more than 4 weeks and less than 6 weeks have elapsed since the last injection, administer the injection as soon as possible. If more than 6 weeks have elapsed since the last injection, restart treatment with either 1-day initiation or 14-day initiation with ABILIFY MAINTENA [see Dosage and Administration (2.2) ] . 2.4 Dosage Modifications for Cytochrome P450 Considerations Refer to Table 1 and Table 2 for dosage modifications for patients who are CYP2D6 poor metabolizers and/or in patients taking concomitant CYP3A4 inhibitors or CYP2D6 inhibitors for greater than 14 days. If the CYP3A4 inhibitor or CYP2D6 inhibitor is withdrawn, the ABILIFY MAINTENA dosage may need to be increased to the previous dose [see Dosage and Administration (2.2) ] . Avoid the concomitant use of CYP3A4 inducers with ABILIFY MAINTENA for greater than 14 days because the blood levels of aripiprazole are decreased and may be below the effective levels. Dosage modifications are not recommended for patients with concomitant use of CYP3A4 inhibitors, CYP2D6 inhibitors or CYP3A4 inducers for less than 14 days. Table 1: Dosage Modifications for ABILIFY MAINTENA (1-Day Initiation) in Patients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers for Greater than 14 days Factors Adjusted Dose No change for oral dosage required during initiation. CYP2D6 Poor Metabolizers Known CYP2D6 Poor Metabolizers 300 mg Known CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors Avoid use Concomitant use with CYP Inhibitors and/or Inducers Strong CYP2D6 or CYP3A4 inhibitors 300 mg CYP2D6 and CYP3A4 inhibitors Avoid use CYP3A4 inducers Avoid use Table 2: Dosage Modifications for ABILIFY MAINTENA (14-Day Initiation) in Patients who are known CYP2D6 Poor Metabolizers and Patients Taking Concomitant CYP2D6 Inhibitors, 3A4 Inhibitors, and/or CYP3A4 Inducers for Greater than 14 days Factors Adjusted Dose No change for oral dosage required during initiation. CYP2D6 Poor Metabolizers Known CYP2D6 Poor Metabolizers 300 mg Known CYP2D6 Poor Metabolizers taking concomitant CYP3A4 inhibitors 200 mg 200 mg and 160 mg dosage adjustment is obtained only by using the 300 mg or 400 mg strength vials. Patients Taking 400 mg of ABILIFY MAINTENA Strong CYP2D6 or CYP3A4 inhibitors 300 mg CYP2D6 and CYP3A4 inhibitors 200 mg CYP3A4 inducers Avoid use Patients Taking 300 mg of ABILIFY MAINTENA Strong CYP2D6 or CYP3A4 inhibitors 200 mg CYP2D6 and CYP3A4 inhibitors 160 mg CYP3A4 inducers Avoid use ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe [see Dosage and Administration (2.6) ] , and 2) Vials [see Dosage and Administration (2.7) ] . 2.5 Aripiprazole Formulations and Kits ABILIFY MAINTENA comes in two types of kits. See instructions for reconstitution/injection/disposal procedures for 1) Pre-filled Dual Chamber Syringe available in 300 mg or 400 mg strength syringes [see Dosage and Administration (2.6) ] , and 2) Single-dose vials available in 300 mg or 400 mg strength vials [see Dosage and Administration (2.7) ] . The 200 mg and 160 mg dosage adjustments are obtained only by using the 300 mg or 400 mg strength vials. 2.6 Pre-filled Dual Chamber Syringe: Preparation and Administration Instructions Preparation Prior to Reconstitution For deep intramuscular deltoid or gluteal injection by healthcare professionals only. Do not administer by any other route. Inject full syringe contents immediately following reconstitution. Administer once monthly. Lay out and confirm that components listed below are provided in the kit: One ABILIFY MAINTENA (aripiprazole) pre-filled dual chamber syringe (400 mg or 300 mg as appropriate) for extended-release injectable suspension containing lyophilized powder and Sterile Water for Injection One 23-gauge, 1-inch (25 mm) hypodermic safety needle with needle protection device for deltoid administration in non-obese patients One 22-gauge, 1.5-inch (38 mm) hypodermic safety needle with needle protection device for gluteal administration in non-obese patients or deltoid administration in obese patients One 21-gauge, 2-inch…

Drug interactions

7 DRUG INTERACTIONS CYP2D6 inhibitors and CYP3A4 Inhibitors : See full prescribing information for ABILIFY MAINTENA dosage modifications when used concomitantly with CYP2D6 inhibitors and/or CYP3A4 inhibitors for greater than 14 days ( 7.1 ) CYP3A4 Inducers : Avoid concomitant use for greater than 14 days ( 7.1 ) See full prescribing information for additional clinically significant drug interactions ( 7.1 ) 7.1 Drugs Having Clinically Important Interactions with ABILIFY MAINTENA Table 9: Clinically Important Drug Interactions with ABILIFY MAINTENA: Concomitant Drug Name or Drug Class Clinical Rationale Clinical Recommendation Strong CYP3A4 Inhibitors (e.g., ketoconazole) or strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine) The concomitant use of oral aripiprazole with strong CYP3A4 or CYP2D6 inhibitors increased the exposure of aripiprazole [see Clinical Pharmacology (12.3) ]. With concomitant use of ABILIFY MAINTENA with a strong CYP3A4 inhibitor or CYP2D6 inhibitor for more than 14 days, reduce the ABILIFY MAINTENA dosage [see Dosage and Administration (2.4) ]. Strong CYP3A4 Inducers (e.g., carbamazepine) The concomitant use of oral aripiprazole and carbamazepine decreased the exposure of aripiprazole [see Clinical Pharmacology (12.3) ]. Avoid use of ABILIFY MAINTENA in combination with carbamazepine and other inducers of CYP3A4 for greater than 14 days [see Dosage and Administration (2.4) ] . Antihypertensive Drugs Due to its alpha-adrenergic antagonism, aripiprazole has the potential to enhance the effect of certain antihypertensive agents. Monitor blood pressure and adjust dose accordingly [see Warnings and Precautions (5.7) ]. Benzodiazepines (e.g., lorazepam) The intensity of sedation was greater with the combination of oral aripiprazole and lorazepam as compared to that observed with aripiprazole alone. The orthostatic hypotension observed was greater with the combination as compared to that observed with lorazepam alone [see Warnings and Precautions (5.7) ]. Monitor sedation and blood pressure. Adjust dose accordingly. 7.2 Drugs Having No Clinically Important Interactions with ABILIFY MAINTENA Based on pharmacokinetic studies with oral aripiprazole, no dosage adjustment of ABILIFY MAINTENA is required when administered concomitantly with famotidine, valproate, lithium, lorazepam [see Clinical Pharmacology (12.3) ] . In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. Additionally, no dosage adjustment is necessary for valproate, lithium, lamotrigine, lorazepam, or sertraline when coadministered with ABILIFY MAINTENA. [See Clinical Pharmacology (12.3) ] .

Common questions

What is Abilify Maintena approved to treat?

According to its FDA label, Abilify Maintena (Aripiprazole LAI Monthly) is approved for: 1 INDICATIONS AND USAGE ABILIFY MAINTENA (aripiprazole) is indicated: for the treatment of schizophrenia in adults for maintenance monotherapy treatment of bipolar I disorder in adults ABILIFY MAINTENA is an atypical antipsychotic indicated: for treatment of schizophrenia in adul… For medical advice, please talk to your prescriber or pharmacist.

What class of drug is Abilify Maintena?

Abilify Maintena (Aripiprazole LAI Monthly) belongs to the Long-Acting Injectable Antipsychotic class of medications.

What form does Abilify Maintena come in?

The FDA label lists Abilify Maintena (Aripiprazole LAI Monthly) as: 3 DOSAGE FORMS AND STRENGTHS For extended-release injectable suspension : 300 mg and 400 mg of lyophilized powder for reconstitution in: single-dose, pre-filled, dual chamber syringe single-dose vial The reconstituted extended-release injectable suspension is a uniform, homogeneous suspension that is opaque and milky-white in color. For extended-release injectable suspension: 300 mg and 400 mg strength lyophilized powder for reconstitution in ( 3 ): single-dose, pre-filled, dual chamber syringe single-dose vial. Available strengths and packaging vary by manufacturer.

Does Abilify Maintena have a Boxed Warning?

Yes. The FDA label for Abilify Maintena (Aripiprazole LAI Monthly) carries a Boxed Warning. Excerpt: "WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. ABILIFY MAINTENA is no…" See the full FDA label for the complete warning. For medical advice, please talk to your prescriber or pharmacist.

How much does Abilify Maintena cost?

Public CMS NADAC pricing for Abilify Maintena (Aripiprazole LAI Monthly) is in the range Retail prices vary widely by pharmacy, insurance, and location. Check with your pharmacy or use tools like GoodRx for current pricing.. Retail price varies by pharmacy, insurance, and manufacturer coupons.

Is Abilify Maintena currently under recall?

The FDA Enforcement Report does not show an active/ongoing recall for Abilify Maintena (Aripiprazole LAI Monthly) in our latest ingest. Recall data can change daily — verify at FDA.gov.

When was Abilify Maintena approved by the FDA?

The FDA record lists the approval date for Abilify Maintena (Aripiprazole LAI Monthly) as 2013-02-28.

Who makes Abilify Maintena?

The FDA label lists Otsuka America Pharmaceutical, Inc. as a labeler/manufacturer of Abilify Maintena (Aripiprazole LAI Monthly). Multiple firms may market generics of the same molecule.

How should Abilify Maintena be stored?

The FDA label states: "Storage Pre-filled dual chamber syringe: Store below 30°C [86°F]. Do not freeze. Protect the syringe from light by storing in the original package until time of use. Vial: Store at 25°C (77°F), excursions permitted betwe…" Follow the packaging insert for the authoritative guidance.

On this site

Related medications in this class or category

Loading full data from Know Your Drugs Institute…